Nasus Pharma Ltd Proceeds from Convertible Debt
Nasus Pharma Ltd (NSRX) reported Proceeds from Convertible Debt of $435.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-03-25
| Period end | Proceeds from Convertible Debt 1 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|
| 2025-12-31 | $435.00K 20-F · filed 2026-03-25 | ||
| 2025-06-30 | $435.00K 6-K · filed 2025-12-29 | ||
| 2024-12-31 | $1.00M 20-F · filed 2026-03-25 | ||
| 2024-06-30 | $951.00K 6-K · filed 2025-12-29 | ||
| 2023-12-31 | $995.00K 20-F · filed 2026-03-25 | ||
| 2023-04-30 | $995.00K 20-F · filed 2026-03-25 | ||
| 2023-03-31 | $995.00K 20-F · filed 2026-03-25 | ||
| 2022-04-30 | $966.00K 20-F · filed 2026-03-25 | ||
| 2022-03-31 | $966.00K 6-K · filed 2025-12-29 |